ADC Therapeutics to Present at Cantor Global Healthcare Conference 2025.

ADC Therapeutics will present at the Cantor Global Healthcare Conference 2025. CEO Ameet Mallik will participate in a fireside chat on September 3, 2025, at 9:10 a.m. ET. A webcast will be available on the company's investor relations site for 30 days post-event. The conference will showcase ADC Therapeutics' strategy and outlook in the field of antibody drug conjugates.

ADC Therapeutics SA (NYSE: ADCT), a leading player in the field of antibody drug conjugates (ADCs), has announced that its Chief Executive Officer, Ameet Mallik, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on September 3, 2025, at 9:10 a.m. ET. The webcast of the presentation will be available via the company's investor relations site for approximately 30 days post-event [1].

ADC Therapeutics is a commercial-stage global leader in ADCs, transforming treatment for patients through its focused portfolio. The company's CD19-directed ADC, ZYNLONTA (loncastuximab tesirine-lpyl), received accelerated approval from the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy [1].

In addition to ZYNLONTA, ADC Therapeutics is advancing IND-enabling activities for a next-generation PSMA-targeting ADC, which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker. The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey, and is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization [1].

The Cantor Global Healthcare Conference 2025 will provide an opportunity for investors and financial professionals to gain insights into ADC Therapeutics' strategy and outlook in the field of ADCs. The fireside chat with CEO Ameet Mallik will likely cover the company's recent developments, future plans, and the broader market landscape for ADCs [1].

References:
[1] https://www.biospace.com/press-releases/adc-therapeutics-to-present-at-the-cantor-global-healthcare-conference-2025